James Samuel Shannon has bought stock on 2 days since Jun 2025
Director at Xilio Therapeutics, Inc., and 1 other company
SEC CIK 0001485417 · Filings on SEC.gov ↗
James Samuel Shannon's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Companies
Every filing
4 filings since Sep 2019, newest first
About James Samuel Shannon
James Samuel Shannon is a pharmaceutical industry executive and board director with significant experience across multiple biotechnology and pharmaceutical companies( He currently serves as a Director of Xilio Therapeutics, Inc. (XLO), a Waltham, Massachusetts-based private biotechnology company specializing in immunotherapeutics and cancer treatments( Shannon has demonstrated active engagement in Xilio Therapeutics through recent insider trading activity, including substantial share purchases in June 2025( His professional portfolio includes directorships at several major pharmaceutical firms: he is a Director of Horizon Therapeutics PLC (HZNP), where he holds approximately 33,604 shares valued at over $4 million, and has held board positions at MannKind Corp (MNKD) and Endocyte Inc (ECYT)( As of 2025, Shannon's estimated net worth is approximately $4-5 million, reflecting his accumulated holdings across these publicly traded pharmaceutical and biotechnology companies(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.